Biologics for the treatment of inflammatory bowel disease in adults: options and switches
10.3760/cma.j.cn101480-20220325-00050
- VernacularTitle:生物制剂治疗成人炎症性肠病：合理选择和转换
- Author:
Pinjin HU
1
Author Information
1. 中山大学附属第六医院消化内科，广州 510655
- Publication Type:Journal Article
- Keywords:
Biologics;
Inflammatory bowel disease;
Infliximab;
Adalimumab;
Vedolizumab;
Ustekinumab;
Options;
Switches
- From:
Chinese Journal of Inflammatory Bowel Diseases
2022;06(2):97-105
- CountryChina
- Language:Chinese
-
Abstract:
Many biologics have been approved for the treatment of inflammatory bowel disease (IBD) . However, due to the lack of head-to-head randomized controlled studies comparing the efficacy and safety of biologics, and the lack of methods to accurately predict the efficacy of biologics, clinicians are often confused about how to select biologics. In this paper, based on the existing clinical evidence, combined with the international mainstream opinion and the application experience of China, suggestions on the options and switches of biologics in the treatment of IBD are put forward for the reference of clinicians.
